[go: up one dir, main page]

HUS1100013I1 - 9-Hidroxi-riszperidon-zsírsav-észterek vizes szuszpenziói, elõállításuk és alkalmazásuk - Google Patents

9-Hidroxi-riszperidon-zsírsav-észterek vizes szuszpenziói, elõállításuk és alkalmazásuk

Info

Publication number
HUS1100013I1
HUS1100013I1 HUS1100013C HUS1100013C HUS1100013I1 HU S1100013 I1 HUS1100013 I1 HU S1100013I1 HU S1100013 C HUS1100013 C HU S1100013C HU S1100013 C HUS1100013 C HU S1100013C HU S1100013 I1 HUS1100013 I1 HU S1100013I1
Authority
HU
Hungary
Prior art keywords
production
fatty acid
acid esters
aqueous suspensions
hydroxyrisperidone fatty
Prior art date
Application number
HUS1100013C
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224016&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUS1100013(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUS1100013I1 publication Critical patent/HUS1100013I1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
HUS1100013C 1996-05-20 2011-08-18 9-Hidroxi-riszperidon-zsírsav-észterek vizes szuszpenziói, elõállításuk és alkalmazásuk HUS1100013I1 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201429 1996-05-20

Publications (1)

Publication Number Publication Date
HUS1100013I1 true HUS1100013I1 (hu) 2017-03-28

Family

ID=8224016

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9901319A HU224025B1 (hu) 1996-05-20 1997-05-12 9-Hidroxi-riszperidon zsírsav-észterek vizes szuszpenziói, előállításuk és alkalmazásuk
HUS1100013C HUS1100013I1 (hu) 1996-05-20 2011-08-18 9-Hidroxi-riszperidon-zsírsav-észterek vizes szuszpenziói, elõállításuk és alkalmazásuk

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9901319A HU224025B1 (hu) 1996-05-20 1997-05-12 9-Hidroxi-riszperidon zsírsav-észterek vizes szuszpenziói, előállításuk és alkalmazásuk

Country Status (38)

Country Link
US (1) US6077843A (hu)
EP (1) EP0904081B1 (hu)
JP (1) JP3274687B2 (hu)
KR (1) KR100358373B1 (hu)
CN (1) CN1093762C (hu)
AR (1) AR007194A1 (hu)
AT (1) ATE208619T1 (hu)
AU (1) AU715572B2 (hu)
BG (1) BG62684B1 (hu)
BR (1) BR9706824B8 (hu)
CA (1) CA2236691C (hu)
CY (2) CY2270B1 (hu)
CZ (1) CZ291284B6 (hu)
DE (2) DE122011100027I1 (hu)
DK (1) DK0904081T3 (hu)
EA (1) EA000536B1 (hu)
EE (1) EE03594B1 (hu)
ES (1) ES2167745T3 (hu)
FR (1) FR11C0035I2 (hu)
HK (1) HK1017852A1 (hu)
HR (1) HRP970276B1 (hu)
HU (2) HU224025B1 (hu)
ID (1) ID16927A (hu)
IL (1) IL124551A (hu)
LU (1) LU91842I2 (hu)
MX (1) MX9804816A (hu)
MY (1) MY126302A (hu)
NO (2) NO315931B1 (hu)
NZ (1) NZ330369A (hu)
PL (1) PL188309B1 (hu)
PT (1) PT904081E (hu)
SI (1) SI0904081T1 (hu)
SK (1) SK284013B6 (hu)
TR (1) TR199800923T2 (hu)
TW (1) TW487572B (hu)
UA (1) UA61898C2 (hu)
WO (1) WO1997044039A1 (hu)
ZA (1) ZA974331B (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72189C2 (uk) * 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
JP2002504505A (ja) * 1998-02-25 2002-02-12 アボット・ラボラトリーズ ブトルファノール持続放出性製剤
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
SI1169024T1 (sl) 1999-03-31 2006-06-30 Janssen Pharmaceutica Nv Predzelatinirani skrob v formulaciji s kontroliranim sproscanjem
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
SK2982003A3 (en) * 2000-08-14 2004-10-05 Teva Pharma Preparation of risperidone
US7666445B2 (en) * 2000-10-20 2010-02-23 The Trustees Of The University Of Pennsylvania Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
GB0216416D0 (en) * 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
NZ570198A (en) * 2002-07-29 2010-01-29 Alza Corp Methods and dosage forms for controlled delivery of paliperidone or risperidone
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
ZA200602347B (en) 2003-10-23 2007-09-26 Otsuka Pharma Co Ltd Controlled release sterile injectable aripiprazole formulation and method
US8329203B2 (en) * 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US20080305140A1 (en) * 2004-01-12 2008-12-11 University Of Pennsylvania Long-Term Delivery Formulations and Methods of Use Thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
PL116330U1 (en) * 2005-10-31 2007-04-02 Alza Corp Method for the reduction of alcohol provoked rapid increase in the released dose of the orally administered opioide with prolonged liberation
WO2008021133A2 (en) 2006-08-09 2008-02-21 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8314110B2 (en) * 2007-04-19 2012-11-20 Youxin Li Compounds for treating mental disorders, and preparation and uses thereof
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
US20090076035A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched paliperidone
KR102163196B1 (ko) * 2007-12-19 2020-10-12 얀센 파마슈티카 엔.브이. 장기 작용성 주사가능 팔리페리돈 에스테르와 관련된 투여 요법
US20090209757A1 (en) * 2008-01-10 2009-08-20 Santiago Ini Processes for the preparation and purification of paliperidone palmitate
US8343140B2 (en) 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
HRP20201179T4 (hr) 2008-09-04 2024-02-16 Amylin Pharmaceuticals, Llc Pripravci s kontinuiranim oslobađanjem na bazi nevodenih nosača
RU2547990C2 (ru) 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
WO2011053829A1 (en) 2009-10-30 2011-05-05 Janssen Pharmaceutical Nv Dosing regimen associated with long-acting injectable paliperidone esters
US20120259116A1 (en) * 2009-12-17 2012-10-11 Rajiv Kumar Novel Process for the Preparation of Paliperidone
TWI577377B (zh) 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
CN107625728A (zh) 2010-10-18 2018-01-26 大日本住友制药株式会社 注射用缓释制剂
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
PL2683717T3 (pl) 2011-05-31 2016-11-30 Wytwarzanie 3-[2-[4-((6-fluoro-1,2-benzoizoksazol-3-ilo)-1-piperydynylo)-6,7,8,9-tetrahydro-9- hydroksy-2-metylo-4H-pirydo[1,2-a]pirymidyn-4-onu (paliperydonu) i palmitynianu paliperydonu
WO2013046225A2 (en) * 2011-08-10 2013-04-04 Glenmark Generics Limited Process for the preparation of paliperidone palmitate
CN102993200B (zh) * 2011-09-10 2016-02-03 鲁翠涛 帕潘立酮氨基酸酯及其制备方法
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US10525057B2 (en) 2013-09-24 2020-01-07 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
MA41917B1 (fr) 2015-04-07 2020-07-29 Janssen Pharmaceuticals Inc Schéma de traitement en cas de doses oubliées pour des esters de palipéridone injectables à action prolongée
WO2016196851A2 (en) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Implant placement and removal systems
IL262802B2 (en) 2016-05-16 2025-04-01 Intarcia Therapeutics Inc Glucagon receptor selective polypeptides and methods of using them
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
KR20230116836A (ko) 2020-11-30 2023-08-04 얀센 파마슈티카 엔.브이. 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법
JP2023552149A (ja) 2020-11-30 2023-12-14 ヤンセン ファーマシューティカ エヌ．ベー． 持続放出パリペリドン注射可能製剤に関連する投与レジメン
CA3203567A1 (en) 2020-11-30 2022-06-02 Janssen Pharmaceutica Nv Methods for ensuring resuspension of paliperidone palmitate formulations
HRP20240074T1 (hr) 2020-11-30 2024-03-29 Janssen Pharmaceutica Nv Režimi za doziranje povezani s injektibilnim formulacijama paliperidona s produljenim oslobađanjem
HUP2100259A1 (hu) 2021-07-07 2023-01-28 Richter Gedeon Nyrt Cariprazine tartalmú szabályozott hatóanyag-leadású injekciós készítmények
IL310909A (en) 2021-08-20 2024-04-01 Janssen Pharmaceutica Nv Dosing regimens associated with extended release paliperidone injectable formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
CA2000786C (en) * 1988-11-07 1999-01-26 Cornelus G. M. Janssen 3-piperidinyl-1,2-benzisoxazoles
US5254556A (en) * 1988-11-07 1993-10-19 Janssen Pharmaceutica N.V. 3-piperidinyl-1,2-benzisoxazoles
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5650173A (en) * 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
EP1649850A1 (en) * 1993-11-19 2006-04-26 Alkermes Controlled Therapeutics Inc. II Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
EP0833820B1 (en) * 1995-06-06 2001-02-14 Aventis Pharmaceuticals Inc. Benzisoxazole and indazole derivatives as antipsychotic agents
US5792477A (en) * 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent

Also Published As

Publication number Publication date
SK284013B6 (sk) 2004-08-03
HRP970276B1 (en) 2002-04-30
HU224025B1 (hu) 2005-05-30
JP3274687B2 (ja) 2002-04-15
NZ330369A (en) 2000-04-28
HK1017852A1 (en) 1999-12-03
EP0904081B1 (en) 2001-11-14
CN1206347A (zh) 1999-01-27
ID16927A (id) 1997-11-20
LU91842I2 (fr) 2011-09-20
TW487572B (en) 2002-05-21
HRP970276A2 (en) 1998-04-30
BG102443A (en) 1999-06-30
FR11C0035I2 (fr) 2013-08-16
PL327995A1 (en) 1999-01-04
CY2011011I2 (el) 2016-12-14
NO2011015I1 (no) 2011-09-19
NO981984D0 (no) 1998-04-30
BR9706824B8 (pt) 2015-02-18
EE9800136A (et) 1998-10-15
KR100358373B1 (ko) 2003-02-11
EP0904081A1 (en) 1999-03-31
DE122011100027I1 (de) 2011-11-17
CY2270B1 (en) 2003-07-04
SK62098A3 (en) 2000-04-10
TR199800923T2 (xx) 1999-09-21
BR9706824A (pt) 1999-03-23
IL124551A0 (en) 1998-12-06
CA2236691C (en) 2007-01-02
MX9804816A (es) 1998-10-31
WO1997044039A1 (en) 1997-11-27
NO981984L (no) 1998-11-19
EE03594B1 (et) 2002-02-15
SI0904081T1 (en) 2002-04-30
AR007194A1 (es) 1999-10-13
CN1093762C (zh) 2002-11-06
MY126302A (en) 2006-09-29
CZ140198A3 (cs) 1999-04-14
CZ291284B6 (cs) 2003-01-15
FR11C0035I1 (hu) 2011-07-10
CY2011011I1 (el) 2016-12-14
EA199800531A1 (ru) 1998-12-24
CA2236691A1 (en) 1997-11-27
ES2167745T3 (es) 2002-05-16
US6077843A (en) 2000-06-20
AU715572B2 (en) 2000-02-03
ZA974331B (en) 1998-11-19
ATE208619T1 (de) 2001-11-15
DE69708284T2 (de) 2002-07-25
DE69708284D1 (de) 2001-12-20
IL124551A (en) 2001-08-26
PT904081E (pt) 2002-04-29
AU2955997A (en) 1997-12-09
DK0904081T3 (da) 2002-02-25
HUP9901319A2 (hu) 1999-08-30
HUP9901319A3 (en) 1999-11-29
EA000536B1 (ru) 1999-10-28
BG62684B1 (bg) 2000-05-31
PL188309B1 (pl) 2005-01-31
KR19990067603A (ko) 1999-08-25
JP2000513718A (ja) 2000-10-17
NO315931B1 (no) 2003-11-17
NO2011015I2 (no) 2013-03-11
UA61898C2 (en) 2003-12-15

Similar Documents

Publication Publication Date Title
HUS1100013I1 (hu) 9-Hidroxi-riszperidon-zsírsav-észterek vizes szuszpenziói, elõállításuk és alkalmazásuk
ZA9810467B (en) Aqueous suspensions of submicron 9-hydroxyrisperidone fatty acid esters.
AU4065200A (en) Zirconia sol and process of making same
ZA9710705B (en) Method for the production of acrolein and acrylic acid.
GB9507415D0 (en) Production and uses of caffeic acid and derivatives thereof
AU5836498A (en) N-acyl-hydroxyamino acid esters and their use
HRP970199A2 (en) New carboxylic acid derivatives, their production and use
HRP970200A2 (en) Novel carboxylic acid derivatives, their production and use
AU6557800A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
ZA9710141B (en) Process for the preparation of salts and esters of clauvulanic acid.
AU6557700A (en) Process for the preparation of substituted 3-phenyl-propanoic acid esters and substituted 3-phenyl-propanoic acids
IL122919A (en) Preparation of 1-alkyl-pyrazole-5- carboxylic acid esters
GB9411539D0 (en) Production and uses of caffeic acid and derivatives thereof
SG65775A1 (en) Process for the production of trimellitic acid and process for the production of trimellitic acid anhydride